Genetic testing to guide infliximab treatment for crohn's disease
Treatments studied
Part of Digestive system clinical trials.
This trial tests whether a person's genetic makeup affects how well infliximab works for treating Crohn's disease. It may help doctors predict which patients benefit most from this medication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and have a Crohn's disease diagnosis confirmed by a medical professional.
- Your Crohn's disease should be moderately to severely active, with a score between 220 and 450 on the CDAI scale.
- You cannot have had treatment with infliximab or any other anti-TNF biologic before.
- You must not be planning pregnancy or breastfeeding within the next 12 months.
- You cannot have certain genetic types (NUDT15 CT or TT) or other serious conditions like active infections, tumors, or major organ diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a more precise way to start infliximab (a Crohn’s medicine) and adjust dosing based on how your body responds. It aims to better control Crohn’s inflammation early and keep it under control.
This trial studies a combination of immune-suppressing treatments for children with Crohn’s disease that is not well controlled. It may help reduce inflammation and improve symptoms if you meet the study’s disease-activity and safety requirements.
This study keeps track of how infliximab works and how safe it is in Chinese children with moderate-to-severe active Crohn’s disease. You may be eligible if this is the first time your child is starting infliximab and you agree to provide study information.
This trial tests whether people with Crohn’s disease or ulcerative colitis who are currently well-controlled can safely use less-frequent anti-TNF medicine. It may help reduce treatment intensity while keeping inflammation under control.
This study tests whether adjusting the dose of infliximab (a biologic medicine given by IV) based on drug levels in your blood works better for treating draining fistulas caused by Crohn's disease. It is for people who have not tried other biologics and whose fistulas have not healed with usual treatments.
This trial is testing a new way to give infliximab, a treatment for moderate to severe Crohn's disease, as a shot under the skin. It's for people who haven't gotten better with other treatments or need strong medication right away.
Hear when a new Infliximab trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.